At present, the therapeutic targets of gastric cancer mainly include HER-2, EGFR, PI3K, mTOR and c-Met, etc., and targeted drugs targeting these receptors and kinases have achieved certain results in the clinical application of gastric cancer treatment (73). This evidence concerns the gene ERBB2 and gastric cancer.